Artemis Medicare Services Limited
Company Analysis
Key Metrics
EPS
3.62
Current ratio
0.98
Debt/Equity
0.83
Debt/EBITDA
2.69
Interest coverage ratio
3.19
Operating Cashflow to total debt
0.29
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Established track record of operation in healthcare industry with resourceful promoters
Experienced management supported by a qualified team of doctors
Growing scale of operations along with improvement in profitability margins in FY24
Diversification of revenue streams
Liquidity: Adequate
Cons
Competition in the healthcare industry in the National Capital Region (NCR)
Exposure to regulatory and concentration risk
Moderate financial risk profile
Stock is trading at 5.29 times its book value
Company has a low return on equity of 10.4% over last 3 years.
Promoters have pledged 44.5% of their holding.
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Artemis Medicare Services Limited bond.
This comprehensive profile covers key factual information about ARTEMIS MEDICARE SERVICES LIMITED. Artemis Medicare Services Limited (AMSL) was incorporated on 2004, by the promoters of the Apollo Tyres Group, is engaged in healthcare business. AMSL operates a 541-bedded multi-specialty tertiary care hospital in Gurgaon. The specialty areas for AMSL include Orthopaedics, Oncology, Cardiovascular, Neurosciences and Bariatric & Minimally Invasive Surgery. ASML has been awarded with the NABH and JCI accreditation. AMSL has also diversified its presence through Artemis Daffodil , Artemis Lite, Artemis Cardiac Care and Artemis Solace models. EPS in Mar-2024 was 3.62. Current ratio in Mar-2024 was 0.98. Debt/Equity in Mar-2024 was 0.83. Debt/EBITDA in Mar-2024 was 2.69. Interest coverage ratio in Mar-2024 was 3.19. Operating Cashflow to total debt in Mar-2024 was 0.29. Total revenue for Mar-2025(E) was ₹924.18. Net income for Mar-2025(E) stood at ₹217.86. Total assets as of Mar-2024 were ₹971.51. Operating cash flow for Mar-2024 was ₹108.85. The company’s borrowing relationships include Axis Bank Limited. (₹N/A Cr), IDFC First Bank Limited. (₹N/A Cr), Axis Bank Limited. (₹N/A Cr), HDFC Bank Limited. (₹N/A Cr), ICICI Bank Limited. (₹N/A Cr), IDFC First Bank Limited. (₹N/A Cr). Peers and comparison entities consist of ARTEMIS MEDICARE SERVICES LIMITED, Kfin Technologies Limited, Indegene Limited, RITES Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: Established track record of operation in healthcare industry with resourceful promoters; Experienced management supported by a qualified team of doctors; Growing scale of operations along with improvement in profitability margins in FY24 ; Diversification of revenue streams; Liquidity: Adequate; . Key risks include: Competition in the healthcare industry in the National Capital Region (NCR); Exposure to regulatory and concentration risk; Moderate financial risk profile; Stock is trading at 5.29 times its book value; Company has a low return on equity of 10.4% over last 3 years.; Promoters have pledged 44.5% of their holding.. Leadership team details include Deepa Gopalan Wadhwa (Independent Director), Devlina Chakravarty (Managing Director), Neeraj Kanwar (Non Executive Director), Nirmal Kumar Ganguly (Non Executive Director), Onkar Kanwar (Chairman & Non-Exe.Director), Poonam Makkar (Company Secretary & Compliance Officer), Sanjaya Baru (Independent Director), Sanjib Sen (Independent Director), Sanjiv Kumar Kothari (Chief Financial Officer), Shalini Kanwar Chand (Non Executive Director), Subbaraman Narayan (Independent Director), Sunil Tandon (Independent Director). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.